Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis

Stem Cells

Volumn 25, Issue 9, 2007, Pages 2363-2370

  Hung, Shih Chieh ^a,b,c   Pochampally, Radhika R ^a   Chen, Sy Chi ^b   Hsu, Shu Ching ^a   Prockop, Darwin J ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; Apoptosis; Bone marrow stromal cells; Endothelial cell; Human aortic endothelial cells; Hypoxia; Interleukin 6; Therapeutic potential

Indexed keywords

INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; TRANSCRIPTION FACTOR IIIA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MALE; MULTIPOTENT STEM CELL; NORMAL HUMAN;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOGENESIS INDUCING AGENTS; APOPTOSIS; CELL HYPOXIA; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOKINES; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; MULTIPOTENT STEM CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 34748845732     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2006-0686     Document Type: Article

References (24)

1. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-74.
2. Nagaya N, Fujii T, Iwase T et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol 2004;287:H2670-2676.
3. Iihoshi S, Honmou O, Houkin K et al. A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res 2004;1007:1-9.
4. Murphy JM, Fink DJ, Hunziker EB et al. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003;48:3464-3474.
5. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313.
6. Koc ON, Day J, Nieder M et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-222.
7. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bonemarrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004;364:141-148.
8. Chen J, Zhang ZG, Li Y et al. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res 2003;92:692-699.
9. Silva GV, Litovsky S, Assad JAR et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005;111:150-156.
10. Kinnaird T, Stabile E, Burnett MS et al. Local delivery of marrowderived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004;109:1543-1549.
11. Gnecchi M, He H, Liang OD et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367-368.
12. Tang YL, Zhao Q, Qin X et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg 2005;80:229-236.
13. Sekiya I, Larson BL, Smith JR et al. Expansion of human adult stem cells from bone marrow stroma: Conditions that maximize the yields of early progenitors and evaluate their quality. STEM CELLS 2002;20:530-541.
14. Schwab G, Siegall CB, Aarden LA et al. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991;77:587-593.
15. Franke TF, Kaplan DR, Cantley LC et al. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997;275:665-668.
16. Jiang BH, Zheng JZ, Aoki M et al. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 2000;97:1749-1753.
17. Gruber R, Kandler B, Holzmann P et al. Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. Tissue Eng 2005;11:896-903.
18. Majumdar MK, Thiede MA, Haynesworth SE et al. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 2000;9:841-848.
19. Takai K, Hara J, Matsumoto K et al. Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis. Blood 1997;89:1560-1565.
20. Labouyrie E, Dubus P, Groppi A et al. Expression of neurotrophins and their receptors in human bone marrow. Am J Pathol 1999;154:405-415.
21. Kim HS, Skurk C, Thomas SR et al. Regulation of angiogenesis by glycogen synthase kinase-3beta. J Biol Chem 2002;277:41888-41896.
22. Kops GJ, Dansen TB, Polderman PE et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002;419:316-321.
23. Potente M, Urbich C, Sasaki K et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 2005;115:2382-2392.
24. Hiasa K, Ishibashi M, Ohtani K et al. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: Next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004;109:2454-2461.